A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours-Reference-Cited by-同舟云学术

A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours

Published:2013-10-20 Issue:6 Volume:72 Page:1343-1352
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Horsley Laura, ,Cummings Jeff,Middleton Mark,Ward Tim,Backen Alison,Clamp Andrew,Dawson Martin,Farmer Hayley,Fisher Nita,Halbert Gavin,Halford Sarah,Harris Adrian,Hasan Jurjees,Hogg Philip,Kumaran Gireesh,Little Ross,Parker Geoff J. M.,Potter Paula,Saunders Mark,Roberts Caleb,Shaw Danielle,Smith Nigel,Smythe Jon,Taylor Andrew,Turner Helen,Watson Yvonne,Dive Caroline,Jayson Gordon C.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-013-2320-9.pdf

Reference25 articles.

1. Brookes K, Cummings J, Backen A, Greystoke A, Ward T, Jayson GC, Dive C (2010) Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs. Br J Cancer 102:1524–1532

2. Cummings J, Langdon SP, Ritchie AA, Burns DJ, Mackay J, Stockman P, Leonard RC, Miller WR (1996) Pharmacokinetics, metabolism and tumour disposition of 8-chloroadenosine 3′,5′-monophosphate in breast cancer patients and xenograft bearing mice. Ann Oncol 7:291–296

3. Cummings J, Ranson M, Lacasse E, Ganganagari JR, St-Jean M, Jayson G, Durkin J, Dive C (2006) Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 95:42–48

4. Cummings J, Ward TH, Lacasse E, Lefebvre C, St-Jean M, Durkin J, Ranson M, Dive C (2005) Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 92:532–538

5. Dilda PJ, Decollogne S, Weerakoon L, Norris MD, Haber M, Allen JD, Hogg PJ (2009) Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol. J Med Chem 52:6209–6216

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. (2,6-Dimethylphenyl)arsonic Acid Induces Apoptosis through the Mitochondrial Pathway, Downregulates XIAP, and Overcomes Multidrug Resistance to Cytostatic Drugs in Leukemia and Lymphoma Cells In Vitro;International Journal of Molecular Sciences;2024-04-26

2. Discovery of novel organoarsenicals as robust thioredoxin reductase inhibitors for oxidative stress mediated cancer therapy;Biochemical Pharmacology;2023-12

3. Reprogramming Energy Metabolism with Synthesized PDK Inhibitors Based on Dichloroacetate Derivatives and Targeted Delivery Systems for Enhanced Cancer Therapy;Journal of Medicinal Chemistry;2023-09-09

4. Targeting mitochondria as a potential therapeutic strategy against chemoresistance in cancer;Biomedicine & Pharmacotherapy;2023-04

5. A first-in-human study of [68Ga]Ga-CDI: a positron emitting radiopharmaceutical for imaging tumour cell death;European Journal of Nuclear Medicine and Molecular Imaging;2022-07-02